KYMR Share Price | Kymera Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Kymera Therapeutics, Inc.?

Market Cap: As of Jun 18, Kymera Therapeutics, Inc. has a market capitalization of 3,018.29 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Kymera Therapeutics, Inc. reported net sales of 58.88 million and a net profit of -240.88 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 835.62 million and total assets of 978.03 million.

Q: What does Kymera Therapeutics, Inc. do?

Overview: Kymera Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.Financial Snapshot: Most recent Net Sales: 22 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -66 Million (Quarterly Results - Mar 2025) Market-cap: USD 3,018.29 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.57 Return on Equity: -30.64% Price to Book: 3.84Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Should I buy, sell or hold Kymera Therapeutics, Inc.?

Based on the current situation of Kymera Therapeutics, Inc., it would be advisable to consider selling your shares. The company has shown poor long-term growth, with an operating profit decline of -239.33% over the past five years. Additionally, it has reported negative results for the last three consecutive quarters, with net sales decreasing by -49.3% and a significant net profit loss of -135.06%. The operating cash flow is also concerning, sitting at a low of -234.06 million USD.Furthermore, the company is facing risks with a negative EBITDA and has not generated any returns over the past year, while profits have dropped by -60.9%. Given these factors, holding or buying more shares could be risky at this time.

Q: Is Kymera Therapeutics, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for Kymera Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance in both time frames. Daily moving averages are bullish, while the KST shows a mildly bearish signal on both weekly and monthly charts. Dow Theory indicates a mildly bullish trend as well. The stock has outperformed the S&P 500 over multiple periods, with a 1-week return of 10.74% compared to 1.05% for the benchmark, and a year-to-date return of 27.17% against 12.22%. Overall, the current technical stance is mildly bullish, supported by strong momentum indicators and positive returns relative to the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

596.54 k

Shareholding (Dec 2025)

FII

11.56%

Held by 129 FIIs

DII

29.84%

Held by 53 DIIs

Promoter

16.63%

How big is Kymera Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Kymera Therapeutics, Inc. has a market capitalization of $3.02 billion, with net sales of $58.88 million and a net profit of -$240.88 million over the last four quarters. The company reported shareholder's funds of $835.62 million and total assets of $978.03 million as of Dec 24.

View full answer

What does Kymera Therapeutics, Inc. do?

22-Jun-2025

Kymera Therapeutics, Inc. is a small-cap biotechnology company focused on pharmaceuticals, reporting net sales of $22 million and a net loss of $66 million as of March 2025. The company has a market cap of approximately $3.02 billion and does not currently pay dividends.

View full answer

Should I buy, sell or hold Kymera Therapeutics, Inc.?

22-Jun-2025

Is Kymera Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Kymera Therapeutics, Inc. has a mildly bullish technical trend, supported by positive MACD and Bollinger Bands indicators, daily moving averages, and strong performance relative to the S&P 500.

View full answer

Compare Kymera Therapeutics, Inc. with Similar Stocks

Apogee Therapeutics, Inc.Inhibrx, Inc.Axcella Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -239.31% of over the last 5 years

The company has declared negative results for the last 3 consecutive quarters

Risky -

Reducing Promoter Confidence

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6,499 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.52

Return on Equity

-30.78%

Price to Book

6.87

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Dec 2025)

Net Profit:

-87 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.48%

6 Months

41.75%

1 Year

120.83%

2 Years

82.76%

3 Years

153.73%

4 Years

75.98%

5 Years

81.51%

Kymera Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

13.63%

EBIT Growth (5y)

-239.31%

EBIT to Interest (avg)

-158.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.57

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.87

EV to EBIT

-18.29

EV to EBITDA

-18.76

EV to Capital Employed

13.22

EV to Sales

137.35

PEG Ratio

Dividend Yield

ROCE (Latest)

-72.28%

ROE (Latest)

-30.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 68 Schemes (41.96%)

Foreign Institutions

Held by 129 Foreign Institutions (11.56%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 3.57% vs -75.65% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -5.84% vs -7.31% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.90",
          "val2": "2.80",
          "chgp": "3.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-95.90",
          "val2": "-86.50",
          "chgp": "-10.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-3.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-87.00",
          "val2": "-82.20",
          "chgp": "-5.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34,110.10%",
          "val2": "-32,078.90%",
          "chgp": "-203.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -16.77% vs -40.08% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -39.08% vs -52.31% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "39.20",
          "val2": "47.10",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-337.20",
          "val2": "-249.30",
          "chgp": "-35.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.20",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.90",
          "val2": "-4.90",
          "chgp": "20.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-311.40",
          "val2": "-223.90",
          "chgp": "-39.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8,812.40%",
          "val2": "-5,453.60%",
          "chgp": "-335.88%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

2.90

2.80

3.57%

Operating Profit (PBDIT) excl Other Income

-95.90

-86.50

-10.87%

Interest

0.10

Exceptional Items

0.00

-3.90

100.00%

Consolidate Net Profit

-87.00

-82.20

-5.84%

Operating Profit Margin (Excl OI)

-34,110.10%

-32,078.90%

-203.12%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 3.57% vs -75.65% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -5.84% vs -7.31% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

39.20

47.10

-16.77%

Operating Profit (PBDIT) excl Other Income

-337.20

-249.30

-35.26%

Interest

0.40

0.20

100.00%

Exceptional Items

-3.90

-4.90

20.41%

Consolidate Net Profit

-311.40

-223.90

-39.08%

Operating Profit Margin (Excl OI)

-8,812.40%

-5,453.60%

-335.88%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -16.77% vs -40.08% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -39.08% vs -52.31% in Dec 2024

All Annual Results

Company CV

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available